



CONTACT: Maria Gordon Shydlo/Deanna Decker
Padilla Speer Beardsley
(212) 752-8338

FOR IMMEDIATE RELEASE

**TOTECT™ NOW AVAILABLE FROM TOPOTARGET USA
- First and Only FDA-Approved Treatment for Anthracycline Extravasation -**

ROCKAWAY, N.J. (October 16, 2007) – TopoTarget USA, Inc., the U.S. subsidiary of TopoTarget A/S, a Denmark-based biotechnology firm specializing in cancer treatment, announced today that Totect™ (dexrazoxane hydrochloride for injection) is now available to cancer treatment facilities throughout the United States through its distributor ASD Healthcare and Oncology Supply, both AmeriSource Bergen companies. Totect™ is the one and only treatment approved by the U.S. Food and Drug Administration (FDA) for extravasation from intravenous anthracycline chemotherapy, the accidental leakage of chemotherapy drugs into surrounding tissue. The company received approval, under an orphan drug designation, from the FDA on September 6, 2007.

“While the number of patients who may be victims of this terrible accident may be low, the cost to these patients and their families, the facilities and the health care system overall can be astronomical,” said John L. Parsons, president of TopoTarget USA, Inc. “It is sometimes difficult to prevent an extravasation from occurring, but oncology nurses and physicians now have a way to reduce tissue damage.”

"This is a great day for some very unfortunate patients," said Robert Dorr, Ph.D, R.Ph., professor of pharmacology and toxicology, director of the pharmacology program at the Arizona Cancer Center.

More than 500,000 doses of intravenous anthracycline chemotherapy are administered in the United States each year. Each time an anthracycline is given, there is a risk of extravasation.

According to Parsons, an estimated 3,600 oncology centers in the United States could benefit from having a Totect™ kit available in the event of an anthracycline extravasation. TopoTarget USA will invest in extensive education to raise awareness of anthracycline extravasations, their prevention, early detection and treatment should an anthracycline extravasation occur. The company has recruited oncology specialists in 10 U.S. geographical regions to support its education/sales program. TopoTarget A/S, the parent company, distributes this treatment in Europe under the name Savene™.

Extravasation occurs when intravenously administered chemotherapy drugs accidentally leak out into surrounding tissue. This can occur if a patient is receiving anthracycline chemotherapy intravenously or through a surgically placed port. Extravasation with anthracyclines can lead to severe and cumulative tissue necrosis including serious damage of the surrounding skin, subcutaneous tissue, muscles and nerves. Currently, most patients who have experienced an anthracycline extravasation need surgery to remove the damaged tissue and may require plastic surgery. In addition, a patient may not be able to continue with chemotherapy until the damaged area heals.

“This treatment may prevent significant injury to the chemotherapy patient and may save hundreds of thousands of dollars in medical costs and other expenses that can result from this unfortunate incident, if it occurs,” said Douglas Reintgen, M.D., director of the Lakeland Regional Cancer Center, Lakeland, Fla.

In the event of an anthracycline extravasation, early detection and rapid Totect™ treatment can reduce healthy tissue damage. In TopoTarget’s clinical trials, only one of the 57 evaluable patients required surgery, while 13 had late sequelae at the event, including pain, fibrosis, atrophy and local sensory disturbance, which did not require surgery.

In addition to its orphan drug exclusivity, Totect™ is a patent-protected product.

For general information on Totect™, please visit www.totect.com or call (866) 914-2922. To order Totect™, please call (800) 746-6273. Full prescribing information, including clinical trial information, safety, dosing, drug interactions and contraindications is available at www.fda.gov/cder/foi/label/2007/022025l1bl.pdf.

About TopoTarget

TopoTarget (OMX: TOPO) is a biotechnology company, headquartered in Denmark with subsidiaries in the United States, Switzerland, Germany and the United Kingdom, dedicated to finding "answers for cancer" and developing improved cancer therapies. TopoTarget was founded and is run by clinical cancer specialists, and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. The company focuses on highly predictive cancer models and key cancer targets (including HDACi, NAD+, mTOR, FASligand and topoisomerase II inhibitors) and has built a strong development foundation. TopoTarget has a broad portfolio of small molecule preclinical drug candidates and eight drugs (both small molecules and protein-based) are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™/Totect™ was approved by the European Medicines Agency (EMA) in 2006 and the FDA in 2007, respectively, and is TopoTarget's first product on the market. For more information, go to www.topotarget.com.

###

TopoTarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: the risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products, processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability exposure. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.